H19 and fatty liver disease: H19 was found to promote hepatic steatosis by increasing the expression of the lipogenic transcription factor MLX interacting protein like (ChREBP) and enhancing lipid accumulation in hepatocytes, which was effectively blocked by the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/mTOR inhibitor PF-04691502.